{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28PBO%29+oral+capsules", "query": { "intervention": "Placebo (PBO) oral capsules" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28PBO%29+oral+capsules&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T02:28:36.599Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03247556", "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "400mg SPN-812", "type": "DRUG" }, { "name": "600mg SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 297, "start_date": "2017-11-20", "completion_date": "2019-02-14", "has_results": true, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 14, "location_summary": "Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Lauderhill", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247556" }, { "nct_id": "NCT02633527", "title": "Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "100mg SPN-812", "type": "DRUG" }, { "name": "200mg SPN-812", "type": "DRUG" }, { "name": "300mg SPN-812", "type": "DRUG" }, { "name": "400mg SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 222, "start_date": "2016-02-01", "completion_date": "2016-07-25", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 1, "location_summary": "Maitland, Florida", "locations": [ { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02633527" }, { "nct_id": "NCT00357994", "title": "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Parkinson's Disease" ], "interventions": [ { "name": "Levodopa carbidopa intestinal gel (LCIG)", "type": "DRUG" }, { "name": "Placebo gel", "type": "DRUG" }, { "name": "Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets", "type": "DRUG" }, { "name": "Placebo (PBO) oral capsules", "type": "DRUG" }, { "name": "CADD-Legacy® 1400 ambulatory infusion pump", "type": "DEVICE" }, { "name": "PEG tube", "type": "DEVICE" }, { "name": "J-tube", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 36, "start_date": "2009-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2015-01-16", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 8, "location_summary": "Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00357994" }, { "nct_id": "NCT04080427", "title": "Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "Placebo capsule", "type": "DRUG" }, { "name": "Dronabinol 7.5 milligram oral capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 102, "start_date": "2021-04-15", "completion_date": "2025-05-31", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04080427" }, { "nct_id": "NCT01107496", "title": "Evaluation of Immediate-Release Viloxazine in Adults With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "IR Viloxazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 52, "start_date": "2010-06", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 4, "location_summary": "Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more", "locations": [ { "city": "Bradenton", "state": "Florida" }, { "city": "Libertyville", "state": "Illinois" }, { "city": "Owensboro", "state": "Kentucky" }, { "city": "Herndon", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107496" }, { "nct_id": "NCT03247517", "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "200mg SPN-812", "type": "DRUG" }, { "name": "400mg SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 310, "start_date": "2017-11-02", "completion_date": "2018-10-17", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 12, "location_summary": "Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247517" }, { "nct_id": "NCT03247530", "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "100mg SPN-812", "type": "DRUG" }, { "name": "200mg SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 477, "start_date": "2017-10-20", "completion_date": "2018-09-12", "has_results": true, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 7, "location_summary": "Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Rochester", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247530" }, { "nct_id": "NCT07593222", "title": "Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Major Depression", "Healthy Participants" ], "interventions": [ { "name": "Sham iTBS", "type": "DEVICE" }, { "name": "TMS", "type": "DEVICE" }, { "name": "D-cycloserine", "type": "DRUG" }, { "name": "Dextromethophan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-09-01", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07593222" }, { "nct_id": "NCT03247543", "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "200mg SPN-812", "type": "DRUG" }, { "name": "400mg SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 313, "start_date": "2017-10-31", "completion_date": "2018-10-17", "has_results": true, "last_update_posted_date": "2021-07-08", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 10, "location_summary": "Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Lauderhill", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247543" }, { "nct_id": "NCT02069366", "title": "Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Post-Traumatic Stress Disorder" ], "interventions": [ { "name": "Dronabinol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 86, "start_date": "2014-11", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-28T02:28:36.599Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02069366" } ] }